<DOC>
	<DOC>NCT01197781</DOC>
	<brief_summary>This Study evaluates the possible drug interaction between FosD and verapamil when taken together.</brief_summary>
	<brief_title>Evaluation of the Drug-drug Interaction Between FosD and Verapamil When Taken Together in Healthy Volunteers</brief_title>
	<detailed_description>An Open-label, Single-Centre Study to Assess the Pharmacokinetics of R406 in Healthy Volunteers when Fostamatinib Disodium 150 mg is Administered Alone and in Combination with Verapamil.</detailed_description>
	<mesh_term>Verapamil</mesh_term>
	<criteria>Weight of at least 50 kg (110 lbs) and body mass index (BMI) between 18 and 35 kg/m2, inclusive. Females must be of nonchildbearing potential History of clinically significant disease or disorder or presence of GI, hepatic or renal disease Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of the drug Any clinically significant abnormalities in lab safety tests or vital signs as results as judged by the Investigator Use of prescription or overthecounter drugs within 2 weeks of first administration of investigational product Current smokers or use of nicotine products within 1 month prior to enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Phase I</keyword>
	<keyword>FosD</keyword>
	<keyword>fostamatinib disodium</keyword>
	<keyword>verapamil</keyword>
	<keyword>healthy volunteers</keyword>
</DOC>